Baekje Shenzhou Baiyue Ze has received FDA accelerated approval for the treatment of recurrent or refractory follicular lymphoma
小新11
发表于 2024-3-10 20:06:33
3782
0
0
Recently, BeiGene announced that Baiyue Ze& Reg; Zebutinib has been granted accelerated approval by the US Food and Drug Administration (FDA) for use in combination with the anti-CD20 monoclonal antibody Otuzumab to treat adult patients with recurrent or refractory (R/R) follicular lymphoma (FL) who have undergone at least second-line systemic treatment. This approval also marks the approval of the fifth indication for B-cell malignancy by Baiyue Ze in the United States.
Mehrdad Mobasher, Chief Medical Officer of Haematology at Baekje, said, "The accelerated approval of Baekje is of great significance as it provides the first and only BTK inhibitor treatment option for American follicular lymphoma patients who have failed initial treatment or have relapsed.". Baiyue Ze is the only BTK inhibitor that has shown efficacy in this type of malignant tumor to date. It has been approved for five tumor indications and has the widest coverage of indications among similar drugs worldwide. This fully demonstrates the differentiated clinical characteristics of Baiyue Ze, as well as our unwavering determination to bring this important treatment option to patients worldwide
Baiyue Ze has been approved for multiple indications in 70 markets worldwide, including the United States, the European Union, the United Kingdom, Canada, Australia, China, South Korea, and Switzerland, and is currently developing more indications worldwide. As of now, the Baiyue Ze Global Clinical Development Project has enrolled over 5000 participants in 29 countries and regions.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- BeiGene: Chief Financial Officer Wang Aijun will resign on July 19th
- Company Review | BeiGene has suffered continuous losses in the past 7 years, and its stock price is under pressure. Can the new CFO bring a turning point?
- More than 40% reduction in losses in the first half of the year, but multiple peers have achieved profits. BeiGene is facing increasing peer pressure
- AbbVie sues for infringement again, BeiGene denies allegations: this move is intended to prevent project development
- Domestic innovative drug leader faces another 'patent challenge': AbbVie accuses BTK degradation agent of infringement, causing BeiGene's stock price to suffer a setback
- BeiGene denies AbbVie's accusation of "stealing trade secrets": will launch a firm defense and development projects will not be interrupted as a result
- BeiGene responds to AbbVie's lawsuit alleging theft of trade secrets: with the intention of obstructing the development process
- BeiGene executive Yin Min is under investigation after previously serving at AstraZeneca | News
- A senior executive of BeiGene has been investigated, and insiders say that the reason for the investigation is unrelated to BeiGene
- BeiGene executive Yin Min is suspected of smuggling and cooperating with the investigation
-
随着“银十”结束,各家造车新势力都交出了一份亮眼的成绩单。 理想领跑10月新势力交付榜,鸿蒙智行重回4万辆,零跑、深蓝、极氪、小鹏等单月交付量均创新高,岚图、阿维塔、智己等实现破万,但哪吒却消失在 ...
- fanadam
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
为期超七周的大罢工终于落下帷幕。 当地时间11月4日,波音美国西海岸工厂工人们就改进后的合同提案投票。 随后,代表着波音超过33000名西雅图地区机械师的IAM工会经表决,以59%的同意票决定接纳波音提 ...
- cristianna
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
“新四化”的时代浪潮下,新能源汽车行业百家争鸣。伴随着自主品牌不断崛起,合资品牌当下的生存状况备受外界关注,如何打好电动化时代的突围战,成为合资品牌的新课题。 作为国内合资车企的代表之一,上汽 ...
- mbgg2797
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
证券时报网讯,热门中概股美股盘前普涨,小鹏汽车、哔哩哔哩涨近5%,蔚来涨超4%,阿里巴巴、拼多多涨超2%。
- p609520
- 3 天前
- 支持
- 反对
- 回复
- 收藏